
Malignant Pleural Effusion - Pipeline Insight, 2025
Description
DelveInsight’s, “Malignant Pleural Effusion - Pipeline Insight, 2025” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Malignant Pleural Effusion pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Malignant Pleural Effusion: Overview
A malignant pleural effusion (MPE) is the buildup of fluid and cancer cells that collects between the chest wall and the lung. This can cause to feel short of breath and/or have chest discomfort. It is a fairly common complication in a number of different cancers. An MPE forms when cells from either a lung cancer or another type of cancer spread to the pleural space. These cancer cells increase the production of pleural fluid and cause decreased absorption of the fluid. People with lung cancer, breast cancer, and lymphoma (a cancer of lymphatic tissue) are most likely to get a MPE. Mesothelioma (a rare cancer of the pleura itself) is another common cause of MPE. Other causes of MPE include cancer that has spread from the stomach, kidney, ovaries, and colon. The symptoms of a MPE can be extremely variable and range from having no symptoms in some people to being very bothersome in others. Common symptoms: Shortness of breath at rest or with activity, chest pain or pressure, cough, pain when taking a deep breath, or the feeling of not being able to take a deep, satisfying breath, fever and Fatigue. Healthcare provider may first suspect that person has MPE on physical examination. To see if the person have MPE and estimate how much fluid is present, patient will have one or more of the imaging tests: Chest X-Ray: A picture showing a view of the chest, including the heart and lungs, CT Scan of the Chest: Multiple pictures of the chest that gives a lot more detail and information than a chest X-ray, Ultrasound of the Chest: One of the best methods of imaging the pleural space. Ultrasound does not involve any radiation and can also be used to help guide procedures to sample or drain pleural fluid. Medical oncologists (specialists who treat cancer) and radiation oncologists may treat the underlying cancer with chemotherapy, immunotherapy and/or radiation to prevent the fluid from accumulating.
""Malignant Pleural Effusion - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Malignant Pleural Effusion pipeline landscape is provided which includes the disease overview and Malignant Pleural Effusion treatment guidelines. The assessment part of the report embraces, in depth Malignant Pleural Effusion commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Malignant Pleural Effusion collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Malignant Pleural Effusion report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Malignant Pleural Effusion Emerging Drugs
Further product details are provided in the report……..
Malignant Pleural Effusion: Therapeutic Assessment
This segment of the report provides insights about the different Malignant Pleural Effusion drugs segregated based on following parameters that define the scope of the report, such as:
Malignant Pleural Effusion: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Malignant Pleural Effusion therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Malignant Pleural Effusion drugs.
Malignant Pleural Effusion Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Malignant Pleural Effusion: Overview
A malignant pleural effusion (MPE) is the buildup of fluid and cancer cells that collects between the chest wall and the lung. This can cause to feel short of breath and/or have chest discomfort. It is a fairly common complication in a number of different cancers. An MPE forms when cells from either a lung cancer or another type of cancer spread to the pleural space. These cancer cells increase the production of pleural fluid and cause decreased absorption of the fluid. People with lung cancer, breast cancer, and lymphoma (a cancer of lymphatic tissue) are most likely to get a MPE. Mesothelioma (a rare cancer of the pleura itself) is another common cause of MPE. Other causes of MPE include cancer that has spread from the stomach, kidney, ovaries, and colon. The symptoms of a MPE can be extremely variable and range from having no symptoms in some people to being very bothersome in others. Common symptoms: Shortness of breath at rest or with activity, chest pain or pressure, cough, pain when taking a deep breath, or the feeling of not being able to take a deep, satisfying breath, fever and Fatigue. Healthcare provider may first suspect that person has MPE on physical examination. To see if the person have MPE and estimate how much fluid is present, patient will have one or more of the imaging tests: Chest X-Ray: A picture showing a view of the chest, including the heart and lungs, CT Scan of the Chest: Multiple pictures of the chest that gives a lot more detail and information than a chest X-ray, Ultrasound of the Chest: One of the best methods of imaging the pleural space. Ultrasound does not involve any radiation and can also be used to help guide procedures to sample or drain pleural fluid. Medical oncologists (specialists who treat cancer) and radiation oncologists may treat the underlying cancer with chemotherapy, immunotherapy and/or radiation to prevent the fluid from accumulating.
""Malignant Pleural Effusion - Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Malignant Pleural Effusion pipeline landscape is provided which includes the disease overview and Malignant Pleural Effusion treatment guidelines. The assessment part of the report embraces, in depth Malignant Pleural Effusion commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Malignant Pleural Effusion collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Malignant Pleural Effusion R&D. The therapies under development are focused on novel approaches to treat/improve Malignant Pleural Effusion.
This segment of the Malignant Pleural Effusion report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Malignant Pleural Effusion Emerging Drugs
- LEITP-1009: LIPAC Oncology
- RSO-021: RS Oncology
- SCB-313: Clover Biopharmaceuticals
Further product details are provided in the report……..
Malignant Pleural Effusion: Therapeutic Assessment
This segment of the report provides insights about the different Malignant Pleural Effusion drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Malignant Pleural Effusion
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Malignant Pleural Effusion: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Malignant Pleural Effusion therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Malignant Pleural Effusion drugs.
Malignant Pleural Effusion Report Insights
- Malignant Pleural Effusion Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Malignant Pleural Effusion drugs?
- How many Malignant Pleural Effusion drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Malignant Pleural Effusion?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Malignant Pleural Effusion therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Malignant Pleural Effusion and their status?
- What are the key designations that have been granted to the emerging drugs?
- LIPAC Oncology
- RS Oncology
- Clover Biopharmaceuticals
- Gongwin Biopharm Holdings
- Simcere Pharmaceutical Group
- LEITP-1009
- RSO-021
- SCB-313
- PTS500
- ENDOSTAR
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Malignant Pleural Effusion : Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Malignant Pleural Effusion – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase I/ II)
- Comparative Analysis
- RSO-021: RS Oncology
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name : Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- LEITP-1009: LIPAC Oncology
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Malignant Pleural Effusion Key Companies
- Malignant Pleural Effusion Key Products
- Malignant Pleural Effusion - Unmet Needs
- Malignant Pleural Effusion - Market Drivers and Barriers
- Malignant Pleural Effusion - Future Perspectives and Conclusion
- Malignant Pleural Effusion Analyst Views
- Malignant Pleural Effusion Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.